Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.

about

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis.

P2860

Q35753087-6829C097-4125-4127-AC5E-0018604942F4 Q38585273-22C65894-B190-4EC9-86B2-10BED49925F8

P2860

Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.

Item

http://www.wikidata.org/entity/Q39471968

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@en

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@nl

type

Item

label

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@en

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@nl

prefLabel

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@en

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@nl

P1476

Combined effects of FLT3 and N ...... cute myeloid leukemia in vivo.

@en

P2093

Chunmei Wang

http://www.w3.org/2001/XMLSchema#string

Guangyao Sheng

http://www.w3.org/2001/XMLSchema#string

Jie Lu

http://www.w3.org/2001/XMLSchema#string

Lu Wang

http://www.w3.org/2001/XMLSchema#string

Songting Bai

http://www.w3.org/2001/XMLSchema#string

Yingchao Wang

http://www.w3.org/2001/XMLSchema#string

Yumei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD.

Nuclear factor-kappaB: the enemy within.

Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis.

Deregulation of signaling pathways in acute myeloid leukemia.

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBT.20411

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21928377

http://www.w3.org/2001/XMLSchema#string

P921

NF-κB

Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.

about

P2860

P2860

Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921